AIMC Topic: Clinical Trials as Topic

Clear Filters Showing 11 to 20 of 271 articles

Bayesian mediation analysis using patient-reported outcomes from AI chatbots to infer causal pathways in clinical trials.

PloS one
The integration of artificial intelligence (AI) chatbots into clinical trials offers a transformative approach to collecting patient-reported outcomes (PROs). Despite the increasing use of AI chatbots for real-time, interactive data gathering, system...

Why Clinical Trials Will Fail to Ensure Safe AI.

Journal of medical systems
Recent reports have raised concerns about emergent behaviors in next-generation artificial intelligence (AI) models. These systems have been documented selectively adapting their behaviors during testing to falsify experimental outcomes and bypass re...

Predicting therapeutic clinical trial enrollment for adult patients with low- and high-grade glioma using supervised machine learning.

Science advances
Therapeutic clinical trial enrollment does not match glioma incidence across demographics. Traditional statistical methods have identified independent predictors of trial enrollment; however, our understanding of the interactions between these factor...

Evaluating the Impact of AI-Based Model-Informed Drug Development (MIDD): A Comparative Review.

The AAPS journal
Model-informed drug development (MIDD) methods play critical role to ensure development of efficacious, and safe individualized therapies. The application of artificial intelligence/machine learning (AI/ML) within the field of drug development has ex...

The emerging role of second harmonic generation/two photon excitation for precision digital analysis of liver fibrosis in MASH clinical trials.

Journal of hepatology
Conventional histopathological evaluation of liver biopsy slides has been invaluable in assessing the causes of liver injury, the severity of the underlying disease processes, and the degree of resulting fibrosis. However, the use of conventional his...

Designing Clinical Trials for Patients With Rare Cancers: Connecting the Zebras.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
The field of rare cancer research is rapidly transforming, marked by significant progress in clinical trials and treatment strategies. Rare cancers, as defined by the National Cancer Institute, occur in fewer than 150 cases per million people each ye...

Artificial Intelligence for Clinical Trial Facilitation, Lessons for Inflammatory Bowel Disease: A Scoping Review.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
BACKGROUND & AIMS: Despite major advances in many fields of science and technology, pharmaceutical research and development continues to be inefficient across multiple diseases. Inflammatory bowel disease (IBD) trials are also subject to high failure...

Past, present, and future of exosomes research in cancer: A bibliometric and visualization analysis.

Human vaccines & immunotherapeutics
Cancer seriously threatens the lives and health of people worldwide, and exosomes seem to play an important role in managing cancer effectively, which has attracted extensive attention from researchers in recent years. This study aimed to scientifica...

Artificial intelligence in central-peripheral interaction organ crosstalk: the future of drug discovery and clinical trials.

Pharmacological research
Drug discovery before the 20th century often focused on single genes, molecules, cells, or organs, failing to capture the complexity of biological systems. The emergence of protein-protein interaction network studies in 2001 marked a turning point an...

Synthetic Data in Healthcare and Drug Development: Definitions, Regulatory Frameworks, Issues.

CPT: pharmacometrics & systems pharmacology
With the recent and evolving regulatory frameworks regarding the usage of Artificial Intelligence (AI) in both drug and medical device development, the differentiation between data derived from observed ('true' or 'real') sources and artificial data ...